CAS 1041434-82-5|Peramivir Trihydrate

Introduction：Basic information about CAS 1041434-82-5|Peramivir Trihydrate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Peramivir Trihydrate BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Synonyms

Common Name	Peramivir Trihydrate
CAS Number	1041434-82-5	Molecular Weight	382.453
Density	/	Boiling Point	/
Molecular Formula	C₁₅H₃₄N₄O₇	Melting Point	/
MSDS	/	Flash Point	/

Names

Name	peramivir
Synonym	More Synonyms

Peramivir Trihydrate BiologicalActivity

Description	Peramivir (RWJ 270201; Rapiacta; BCX 1812) is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM.IC50 Value: 0.09 nMTarget: NeuraminidasePeramivir is an experimental antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. It has been authorized for the emergency use of treatment of certain hospitalized patients with known or suspected 2009 H1N1 influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. From Wikipedia
Related Catalog	Signaling Pathways >>Anti-infection >>Influenza VirusResearch Areas >>Infection
References	[1]. Louie JK, Yang S, Yen C, Acosta M, Schechter R, Uyeki TM.Use of Intravenous Peramivir for Treatment of Severe Influenza A(H1N1)pdm09.PLoS One. 2012;7(6):e40261. [2]. Sakata H.Clinical efficiency in children treated with intravenous drip infusion of peramivirJpn J Antibiot. 2011 Dec;64(6):383-7. [3]. Abed Y, Pizzorno A, Boivin G.Therapeutic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H275Y Neuraminidase Mutation.Antimicrob Agents Chemother. 2012 Aug;56(8):4375-80. [4]. Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, Kondo H, Suzuki Y, Saito K, Suzuki H.Clinical effectiveness of neuraminidase inhibitors-oseltamivir, zanamivir, laninamivir, and peramivir-for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.J Infect Chemother. 2012 May 29. [5]. Yu Y, Garg S, Yu PA, Kim HJ, Patel A, Merlin T, Redd S, Uyeki TM.Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.Clin Infect Dis. 2012 Jul;55(1):8-15.

Description

Peramivir (RWJ 270201; Rapiacta; BCX 1812) is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM.IC50 Value: 0.09 nMTarget: NeuraminidasePeramivir is an experimental antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. It has been authorized for the emergency use of treatment of certain hospitalized patients with known or suspected 2009 H1N1 influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. From Wikipedia

Related Catalog

Signaling Pathways >>Anti-infection >>Influenza VirusResearch Areas >>Infection

References

[1]. Louie JK, Yang S, Yen C, Acosta M, Schechter R, Uyeki TM.Use of Intravenous Peramivir for Treatment of Severe Influenza A(H1N1)pdm09.PLoS One. 2012;7(6):e40261.

[2]. Sakata H.Clinical efficiency in children treated with intravenous drip infusion of peramivirJpn J Antibiot. 2011 Dec;64(6):383-7.

[3]. Abed Y, Pizzorno A, Boivin G.Therapeutic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H275Y Neuraminidase Mutation.Antimicrob Agents Chemother. 2012 Aug;56(8):4375-80.

[4]. Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, Kondo H, Suzuki Y, Saito K, Suzuki H.Clinical effectiveness of neuraminidase inhibitors-oseltamivir, zanamivir, laninamivir, and peramivir-for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.J Infect Chemother. 2012 May 29.

[5]. Yu Y, Garg S, Yu PA, Kim HJ, Patel A, Merlin T, Redd S, Uyeki TM.Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.Clin Infect Dis. 2012 Jul;55(1):8-15.

Chemical & Physical Properties

Molecular Formula	C₁₅H₃₄N₄O₇
Molecular Weight	382.453
Exact Mass	382.242737
PSA	179.71000
LogP	1.69890
InChIKey	RFUCJKFZFXNIGB-ZBBHRWOZSA-N
SMILES	CCC(CC)C(NC(C)=O)C1C(N=C(N)N)CC(C(=O)O)C1O.O.O.O

Safety Information

Hazard Codes	Xi

Synonyms

Rapiacta trihydrate

Peramivir Trihydrate

QW7Y7ZR15U

peramivir hydrate

BCX 1812 trihydrate

CS-0732

UNII-QW7Y7ZR15U

(1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid,trihydrate

(1S,2S,3S,4R)-3-[(1S)-1-Acetamido-2-ethylbutyl]-4-[(diaminomethylene)amino]-2-hydroxycyclopentanecarboxylic acid trihydrate

Cyclopentanecarboxylic acid, 3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-[(diaminomethylene)amino]-2-hydroxy-, (1S,2S,3S,4R)-, hydrate (1:3)

Recommended......